MedTrace Logo

Inflammation and Coronary Endothelial Function

NCT02366091 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 111

Last updated 2021-10-21

Study results available
· View outcomes & findings →

Summary

The investigators are studying whether anti-inflammatory agents can improve abnormal coronary artery function in patients with coronary artery disease (CAD) and abnormal coronary artery endothelial function.

Conditions

Interventions

DRUG

Methotrexate

Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease

DRUG

Colchicine

Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.

DRUG

Placebo

Prepared by Johns Hopkins Investigational Drug Service to mimic methotrexate and colchicine.

Sponsors & Collaborators

Principal Investigators

  • Robert G Weiss, MD · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
FACTORIAL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2020-08-01
Completion
2020-09-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02366091 on ClinicalTrials.gov